RNF182, identified as a novel tumour-suppressive E3 ubiquitin ligase, induces p65 ubiquitination, suppressing PDL1 transcription and immune suppression in lung adenocarcinoma, thus mitigating cancer progression (Zeng et al., 2023). This evidence concerns the gene CD274 and lung adenocarcinoma.